Objective To determine the difference between the combination therapy of tamsulosin and escitalopram and conventional therapy in patients with chronic pelvic pain syndrome(CPPS)complicated with anxiety and depression,and to evaluate the clinical application potential of the combination therapy.Methods A total of 150 CPPS patients comor-bid with anxiety and depression admitted to the Department of Urology at the Integrated Traditional Chinese and Western Medicine Hospital in Cangzhou,Hebei Province,from July 2019 to July 2022 were selected.They were randomly divided into an observation group and a control group,with 75 cases in each.The observation group received tamsulosin plus es-citalopram,while the control group received tamsulosin plus a placebo.The effectiveness and safety were compared after a 3-month course of treatment.Results The clinical efficacy showed that the total effective rate in the observation group was significantly higher than that in the control group[96.00％(72/75)vs.84.00％(63/75),P＜0.05].In the ob-servation group,urinary symptoms,pain,and discomfort on the National Institutes of Health chronic prostatitis symptom index scale significantly decreased,and the quality of life dimension improved compared to before(P＜0.05).Compared with the control group,the Hamilton anxiety scale(8.37±1.89 vs.11.85±2.67)and Hamilton depression scale(6.71± 1.64 vs.9.26±2.42)scores in the observation group showed a significant reduction in negative emotional scores.After combined medication,the levels of serum inflammatory factors TNF-α and IL-8 in the observation group were significantly lower than those in the control group(P＜0.05).The total incidence of adverse reactions[9.33％(7/75)vs.12.00％(9/75)]showed no statistically significant difference between the groups(P＞0.05).Conclusion The combination of tamsulosin and escitalopram not only alleviates psychological symptoms and reduces anxiety and depression scores but also improves inflammatory levels and enhances the quality of life in patients with CPPS comorbid with anxiety and depression.This combination therapy demonstrates good safety and effectiveness in patients with this comorbidity and is worthy of pro-motion.
维普
万方数据
